261 related articles for article (PubMed ID: 21144875)
1. Challenges in inhaled product development and opportunities for open innovation.
Forbes B; Asgharian B; Dailey LA; Ferguson D; Gerde P; Gumbleton M; Gustavsson L; Hardy C; Hassall D; Jones R; Lock R; Maas J; McGovern T; Pitcairn GR; Somers G; Wolff RK
Adv Drug Deliv Rev; 2011; 63(1-2):69-87. PubMed ID: 21144875
[TBL] [Abstract][Full Text] [Related]
2. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
Wang YB; Watts AB; Peters JI; Williams RO
Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
[TBL] [Abstract][Full Text] [Related]
3. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product.
Bäckman P; Adelmann H; Petersson G; Jones CB
Clin Pharmacol Ther; 2014 May; 95(5):509-20. PubMed ID: 24503626
[TBL] [Abstract][Full Text] [Related]
4. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
Sakagami M
Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
[TBL] [Abstract][Full Text] [Related]
5. The particle has landed--characterizing the fate of inhaled pharmaceuticals.
Patton JS; Brain JD; Davies LA; Fiegel J; Gumbleton M; Kim KJ; Sakagami M; Vanbever R; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S71-87. PubMed ID: 21133802
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs.
Matera MG; Calzetta L; Ora J; Rogliani P; Cazzola M
Expert Opin Drug Deliv; 2021 Jul; 18(7):891-906. PubMed ID: 33412922
[No Abstract] [Full Text] [Related]
7. Deposition, imaging, and clearance: what remains to be done?
Scheuch G; Bennett W; Borgström L; Clark A; Dalby R; Dolovich M; Fleming J; Gehr P; Gonda I; O'Callaghan C; Taylor G; Newman S
J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S39-57. PubMed ID: 21133799
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Current approaches to the discovery of novel inhaled medicines.
Strong P; Ito K; Murray J; Rapeport G
Drug Discov Today; 2018 Oct; 23(10):1705-1717. PubMed ID: 29775668
[TBL] [Abstract][Full Text] [Related]
10. Optimisation of DMPK by the inhaled route: challenges and approaches.
Cooper AE; Ferguson D; Grime K
Curr Drug Metab; 2012 May; 13(4):457-73. PubMed ID: 22299825
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary formulations: what remains to be done?
Weers JG; Bell J; Chan HK; Cipolla D; Dunbar C; Hickey AJ; Smith IJ
J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S5-23. PubMed ID: 21133800
[TBL] [Abstract][Full Text] [Related]
12. Adaptive Aerosol Delivery (AAD) technology.
Denyer J; Nikander K; Smith NJ
Expert Opin Drug Deliv; 2004 Nov; 1(1):165-76. PubMed ID: 16296727
[TBL] [Abstract][Full Text] [Related]
13. Particle engineering techniques for inhaled biopharmaceuticals.
Shoyele SA; Cawthorne S
Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1009-29. PubMed ID: 17005293
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy.
Mukker JK; Singh RS; Derendorf H
Adv Drug Deliv Rev; 2015 May; 85():57-64. PubMed ID: 25770775
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose Predictions.
Caniga M; Cabal A; Mehta K; Ross DS; Gil MA; Woodhouse JD; Eckman J; Naber JR; Callahan MK; Goncalves L; Hill SE; Mcleod RL; McIntosh F; Freke MC; Visser SA; Johnson N; Salmon M; Cicmil M
J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):362-77. PubMed ID: 26859446
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary drug delivery: medicines for inhalation.
Henning A; Hein S; Schneider M; Bur M; Lehr CM
Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530
[TBL] [Abstract][Full Text] [Related]
17. iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug Products.
Hastedt JE; Bäckman P; Cabal A; Clark A; Ehrhardt C; Forbes B; Hickey AJ; Hochhaus G; Jiang W; Kassinos S; Kuehl PJ; Prime D; Son YJ; Teague S; Tehler U; Wylie J
Mol Pharm; 2024 Jan; 21(1):164-172. PubMed ID: 38059771
[TBL] [Abstract][Full Text] [Related]
18. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.
Tolman JA; Williams RO
Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248
[TBL] [Abstract][Full Text] [Related]
19. Formation, characterization, and fate of inhaled drug nanoparticles.
Zhang J; Wu L; Chan HK; Watanabe W
Adv Drug Deliv Rev; 2011 May; 63(6):441-55. PubMed ID: 21118707
[TBL] [Abstract][Full Text] [Related]
20. Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs.
Bäckman P; Arora S; Couet W; Forbes B; de Kruijf W; Paudel A
Eur J Pharm Sci; 2018 Feb; 113():41-52. PubMed ID: 29079338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
